Sermorelin 5mg
Synthetic GHRH(1-29) analog evaluated for pulsatile pituitary growth hormone release and nocturnal somatotropic axis stimulation in research.
Mechanism
Binds selectively to pituitary GHRH receptors to prompt native, pulsatile growth hormone secretion while preserving physiological somatostatinergic negative feedback.
Dosing
Standard laboratory protocols document an initial nightly baseline starting dose of 100 to 200 mcg administered subcutaneously.
Reconstitution
Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water achieves an experimental working concentration of approximately 1.67 mg/mL (1,667 mcg/mL).
Storage
Keep the lyophilized powder refrigerated between 2 to 8 °C in the dark, and maintain the reconstituted liquid at 2 to 8 °C for up to 10 to 14 days without freezing.
Mix & measure Sermorelin 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Sermorelin 5mg
Vial strength → BAC water → target dose
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (1× nightly) | ~12 units (0.12 mL) |
| Weeks 3–4 | 300 mcg (1× nightly) | ~18 units (0.18 mL) |
| Weeks 5–6 | 400 mcg (1× nightly) | ~24 units (0.24 mL) |
| Weeks 7–8 | 500 mcg (1× nightly) | ~30 units (0.30 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
Provides 5 mg of lyophilized Sermorelin per container (roughly 4 vials needed for an 8-week research course).
Insulin Syringes (U-100)
Facilitates exact microgram liquid measurement using a 1 mL / 100-unit barrel (~56 syringes per 8-week protocol).
Bacteriostatic Water
Supplies 3.0 mL of sterile diluent preserved with benzyl alcohol per 5 mg vial to prepare the liquid solution.
Alcohol Swabs
Employed to sanitize the vial rubber septum and wipe injection sites to uphold aseptic technique.
Why researchers study it
GH & IGF-1 axis stimulation
Age-related somatotropic decline
Slow-wave sleep architecture modulation
Adipocyte lipolysis and lean tissue metabolism
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Sermorelin represents a truncated, biologically active 29-amino-acid synthetic peptide corresponding to the amino-terminal fragment of native human growth hormone-releasing hormone [GHRH(1-29)]. Initially investigated in clinical pharmacology for diagnostic evaluation and pediatric growth deficiencies, contemporary investigations evaluate its regulatory influence on pulsatile endocrine signaling. Because it functions by directly stimulating pituitary somatotropic cells rather than supplying exogenous growth factors, its biological activity remains governed by endogenous somatostatinergic and IGF-1 negative feedback loops. In physiological and cellular models, the compound exhibits an exceedingly rapid biological half-life alongside a distinct downstream pulsatile output. Investigations frequently focus on its structural stability, receptor interaction kinetics, and modulation of downstream markers such as circulating insulin-like growth factor 1 (IGF-1). Scientific inquiry often models nighttime exposure paradigms to align with normal diurnal hormonal peaks. Preclinical research also explores how sustained or titrated exposure profiles alter metabolic signaling, cellular maintenance, lipolysis, and slow-wave sleep physiology. All presented reference concentrations and reconstitution metrics serve solely to facilitate reproducible, accurate volumetric measurements within non-clinical experimental frameworks.
References
- 1.Prakash & Goa, Drugs, 1999 — Review of sermorelin pharmacology and pediatric growth hormone deficiency trials
- 2.RxList, Sermorelin Acetate Monograph, 2008 — Clinical pharmacology, reconstitution parameters, and discontinued status
- 3.PubMed Clinical Review, Nocturnal GH Secretion, 1996 — Diurnal secretion patterns and somatopause dynamics
- 4.Mayo Clinic, Clinical Monograph, 2020 — Proper handling, storage parameters, and solution stability
- 5.RxList, Sermorelin Prescribing Information, 2008 — Safety profile, adverse reaction incidence, and thyroid monitoring
- 6.GHRH Mechanism Studies, PubMed, 2006 — Somatotrope receptor signaling and pituitary negative feedback conservation
- 7.Johns Hopkins Arthritis Center, Subcutaneous Technique Guide, 2021 — Subcutaneous administration and site rotation protocols
- 8.CDC, General Vaccine Administration Protocols, 2021 — Injection angle and no-aspiration guidance
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allTestagen 20mg
Synthetic Khavinson tetrapeptide bioregulator investigated for its role in male reproductive health and endocrine signaling modulation.
View ProtocolKLOW 80mg
Four-component investigative peptide blend designed to study concurrent soft-tissue repair, cellular remodeling, and inflammation modulation.
View ProtocolThymulin 5mg
A zinc-dependent nonapeptide hormone originating from thymic epithelial cells, investigated for its role in T-lymphocyte differentiation.
View Protocol